Conference on Q2 FY2026 (April 1, 2026 to September 30, 2026) Financial Results Toru Kimura, President and CEO Sumitomo Pharma Co., Ltd. October 30, 2026 Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections,…
Conference on Q2 FY2026
(April 1, 2026 to September 30, 2026)
Financial Results
Toru Kimura, President and CEO
Sumitomo Pharma Co., Ltd.
October 30, 2026
Disclaimer Regarding Forward-looking Statements
This material contains forecasts, projections, goals, plans, and other forward-looking statements
regarding the Group’s financial results and other data. Such forward-looking statements are based on
the Company’s assumptions, estimates, outlook, and other judgments made in light of information
available at the time of disclosure of such statements and involve both known and unknown risks and
uncertainties.
Accordingly, due to various subsequent factors, forecasts, plans, goals, and other statements may not
be realized as described, and actual financial results, success/failure or progress of development, and
other projections may differ materially from those presented herein.
Information concerning pharmaceuticals and other products (including those under development)
contained herein is not intended as advertising or as medical advice.
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
1
Financial Results for Q2 FY2026
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
2
Financial Results for Q2 FY2026
Financial Results for Q2 FY2026 (Core Basis)
The forecasts for FY2026 were revised
(See P.8)
Billions of JPY
Q2YTD
FY2025
Results
Q2YTD
FY2026
Results
227.1
89.7
137.4
74.0
17.5
50.1
96.1
266.5
123.5
143.0
78.3
23.8
1.2
42.1
39.4
33.8
5.5
4.4
6.3
(48.9)
(54.0)
0.1
0.2
0.1
Income tax expenses
96.2
(3.4)
92.8
(6.1)
42.3
(2.9)
39.4
1.1
Net profit attributable to owners
of the parent
98.9
38.2
Revenue
Cost of sales
Gross profit
SG&A expenses
R&D expenses
Others (core basis)
Core operating profit
Adjustment items
(negative number indicates net expense)
Operating profit
Finance income/costs
Profit before taxes
Average rates:
Q2 FY2025 Results : 1US$ = ¥146.03
Q2 FY2026 Results : 1US$ = ¥159.49
FY2026 forecasts : 1US$ = ¥155.00
Change
Value
FY2026
July 31 1H Progress
Forecasts
%
FX Impact
%
17.8
8.1
9.7
3.9
1.4
17.3
37.7
4.0
5.9
35.9
251.0 106.2
4.3 (56.2)
30.0 140.4
(53.9)
0.5
(53.4)
7.2
(56.0)
30.0 140.9
(60.6)
(61.3)
(57.6)
Period end rates:
As of the end of March 2026
: 1US$ = ¥159.90
As of the end of September 2026 : 1US$ = ¥157.31
26.0 147.1
Year-on-year
Revenue
Revenue increased primarily due
to growth in the U.S., which more
than offset the decline resulting
from the partial transfer of the
Asian business
Gross profit
Gross profit margin decreased
mainly due to the partial transfer
of the Asian business
R&D expenses
R&D expenses increased due to
accelerated clinical development
in oncology and advancement of
programs in CNS
Vs. 1H Forecast
Core operating profit exceeded
the forecast due to higher-thanexpected sales revenue
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
3
Financial Results for Q2 FY2026
Revenue of Major Products in the U.S.
Q2YTD
FY2025
Results
U.S.
Q2YTD
FY2026
Results
Change
Q2YTD
FY2025
Results
Millions of USD
Q2YTD
FY2026
Results
Change
Value
FX
Impact
FY2026
%
May 13 Forecasts
Millions
of USD
Billions of JPY
JPY-basis
Progress %
Billions
of JPY
®
ORGOVYX
473
681
207
69.1
108.6
39.4
9.2
57.0
1,354 209.9
51.7
GEMTESA®
297
407
110
43.4
64.9
21.5
5.5
49.6
686 106.3
61.0
MYFEMBREE®
43
58
15
6.3
9.3
3.0
0.8
46.8
100
15.4
60.5
RETHYMIC®
22
20
(3)
3.3
3.1
(0.2)
0.3
(5.5)
35
5.4
57.8
APTIOM®
73
16
(57)
10.7
2.5
(8.1)
0.2 (76.2)
35
5.4
47.1
Others*
163
59
(105)
24.2
9.4
(14.8)
0.8 (61.3)
412
63.9
14.6
1,073
1,240
167
157.0
197.8
40.8
16.7
2,622 406.4
48.7
Total
26.0
Average rates:
Q2 FY2025 Results : 1US$ = ¥146.03
Q2 FY2026 Results : 1US$ = ¥159.49
ORGOVYX® and GEMTESA®
revenue increased
significantly year-on-year
APTIOM® revenue decreased
due to loss of exclusivity
The prior-year for "Others"
includes sales milestone
revenue related to
ORGOVYX®
- Major items included in Others
Q2YTD
FY
2025
Results
Deferred revenue from
the collaboration with Pfizer
Sales milestone revenue
related to ORGOVYX®
(sales exceeding $0.5B)
$44M
$100M
Q2YTD
FY 2026
Results
Deferred revenue from
the collaboration with Pfizer
$44M
FY2026
May 13
Forecasts
Deferred revenue from
the collaboration with Pfizer
Sales milestone revenue
related to ORGOVYX®
(sales exceeding $1.0B)
$65M
$325M
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
4
Financial Results for Q2 FY2026
Revenue of Major Products in Japan
Billions of JPY
Q2YTD
FY2025
Results
Q2YTD
FY2026
Results
Change
Value
FY2026
%
May 13
Forecasts
Progress
%
Japan
-
8.2
8.2
-
17.1
48.0
LATUDA®
6.9
7.3
0.4
5.2
13.6
53.3
TWYMEEG®
5.0
6.6
1.6
31.4
11.9
55.1
METGLUCO®
3.7
3.8
0.1
2.8
7.6
49.9
Equa®/EquMet®
7.5
-
(7.5)
-
-
-
AG products
6.1
5.9
(0.1)
(1.9)
11.2
53.1
Others
13.7
12.9
(0.8)
(6.0)
26.2
49.2
42.8
44.6
1.8
4.2
87.6
51.0
XEPLION®/XEPLION TRI®
Total
Commencement of sales of
XEPLION ®/XEPLION TRI ®
Continued sales growth of
TWYMEEG®
Termination of sales partnership for
Equa®/EquMet®
Note: Sales of each product are shown by invoice price
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
5
Financial Results for Q2 FY2026
Gross Profit by Region (Core Basis)
Billions of JPY
Q2YTD Revenue
Cost of sales
FY2026
Results Gross profit
Q2YTD
FY2025
Results
Revenue
Cost of sales
Gross profit
Revenue
Cost of sales
Change
Gross profit
Japan
44.6
25.0
19.6
U.S.
197.8
78.1
119.7
Other
24.1
20.4
3.6
Total
266.5
123.5
143.0
42.8
21.9
21.0
157.0
56.9
100.1
27.3
10.9
16.3
227.1
89.7
137.4
1.8
3.1
40.8
21.2
(3.2)
9.5
39.4
33.8
(1.3)
19.5
(12.7)
5.5
Japan
Gross profit decreased due to the change in
product mix
U.S.
Gross profit increased due to higher revenue
Other
Gross profit decreased due to the partial transfer
of the Asian business
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
6
Financial Forecasts for FY2026
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
7
Financial Forecasts for FY2026
Financial Forecasts for FY2026 (Core Basis)
Billions of JPY
FY2026
FY2026
May 13
Revised
Forecasts Forecasts
Revenue
Cost of sales
Gross profit
SG&A expenses
R&D expenses
Others (core basis)
Core operating profit
Adjustment items
(negative number indicates loss)
Operating profit
Finance income/costs
Income tax expenses
Net profit
Net profit attributable to owners of the parent
R O E
R O I C
Change from Previous Forecasts
Value
540.0
245.0
295.0
155.0
51.0
2.0
91.0
565.0
246.0
319.0
164.0
52.0
2.0
105.0
25.0
1.0
24.0
9.0
1.0
-
14.0
(1.0)
(1.0)
90.0
(6.5)
6.5
77.0
77.0
20.3%
15.1%
104.0
(5.0)
5.0
94.0
94.0
24.1%
17.6%
-
14.0
1.5
(1.5)
17.0
17.0
FX Impact
%
6.1
3.1
3.0
1.5
0.4
4.6
0.4
8.1
5.8
2.0
1.1
15.4
15.6
FX rates:
FY2026
Previous Forecasts : 1US$ = ¥155.00
Revised Forecasts : 1US$ = ¥157.00
Revenue: Revised upward by ¥25.0B
U.S. +¥18.7B :
Higher sales forecast for GEMTESA®
Others +¥5.4B :
Higher forecast for sales to the EU
SG&A:
Higher promotional spending and
licensing expenses in the U.S.
22.1
22.1
Dividend Reinstatement Planned for FY2026 Year-End
Year-end dividend forecast : ¥15 per share
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
8
Financial Forecasts for FY2026
Revenue of Major Products in the U.S.
FY2026
May 13
Forecasts
U.S.
FY2026
Revised
Forecasts
Change
FY2026
May 13
Forecasts
Millions of USD
FY2026
Revised
Forecasts
Change
Value
FX Impact
%
Billions of JPY
ORGOVYX®
1,354
1,359
5
209.9
213.4
3.5
2.7
1.7
GEMTESA®
686
752
66
106.3
118.0
11.7
1.5
11.0
MYFEMBREE®
100
109
10
15.4
17.1
1.7
0.2
11.0
RETHYMIC®
35
38
3
5.4
6.1
0.7
0.1
13.0
APTIOM®
35
33
(2)
5.4
5.2
(0.2)
0.1
(3.7)
Others*
412
415
3
64.0
65.3
1.3
1.0
2.0
2,622
2,708
86
406.4
425.1
18.7
5.6
4.6
Total
FX rates:
FY2026
Previous Forecasts : 1US$ = ¥155.00
Revised Forecasts : 1US$ = ¥157.00
GEMTESA® sales forecast
revised upward to reflect
favorable pricing in 1H
- Major items included in Others
FY2026
May 13
Forecasts
Deferred revenue from
the collaboration with Pfizer
Sales milestone revenue related
to ORGOVYX®
(sales exceeding $1.0B)
$65M
$325M
FY2026
Revised
Forecasts
Deferred revenue from
the collaboration with Pfizer
Sales milestone revenue related
to ORGOVYX®
(sales exceeding $1.0B)
$65M
$325M
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
9
Financial Forecasts for FY2026
ORGOVYX®
Q2 YTD: Performed as planned and achieved 102% of net sales versus original forecast
Annual sales forecast revised upward to $1,359M (+$5M)
Plan for Q2
YTD FY2026
Actual for Q2
YTD FY2026
$681M
$664M
$M
400
Variance Analysis
Between Original and Revised FY2026 Forecasts
Year-over-year
comparison
[$M]
144%
(Achievement: 102%)
1,600
Quarterly Net Sales / Demand Trends*
350
300
1,400
1,354
1,200
325
1,000
250
1,029
1,359
(9)
14
数量
Volume
価格
Price
800
200
600
150
400
100
200
50
0
0
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q
FY
2021
2022
数量
2023
売上
2024
2025
2026
Original
FY2025
Actual FY2026
2025年度実績
2026年度
Forecast
従来予想
FY2026
Revised
2026年度
Forecast
修正予想
Reference: YoY Growth: $331M (+32%) ̶ FY2026 ($1,359M) vs. FY2025
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
*Number of bottles (Internal calculation)
10
Financial Forecasts for FY2026
GEMTESA®
Q2 YTD: Achieved 117% of net sales versus original forecast primarily driven by temporary pricing impacts
Annual sales forecast revised upward to $752M (+$66M)
Plan for Q2
YTD FY2026
$347M
$M
250
Actual for Q2
YTD FY2026
Variance Analysis
Between Original and Revised FY2026 Forecasts
Year-over-year
comparison
$407M
137%
(Achievement: 117%)
[$M]
752
800
Quarterly Net Sales / Demand Trends*
700
200
600
637
686
49
12
54
数量
Volume
価格
Price
500
150
400
300
100
200
50
100
0
0
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q
FY
2021
2022
数量
2023
2024
売上
2025
2026
2025年度実績
2026年度
Original
FY2025
Actual FY2026
Forecast
従来予想
2026年度
FY2026
Revised
Forecast
修正予想
Reference: YoY Growth: $115M (+18%) — FY2026 ($752M) vs. FY2025
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
- Source: Symphony Health, a HealthVerity Company, Metys®, April 2021 to September 2026
11
Financial Forecasts for FY2026
Gross Profit by Region (Core Basis)
Billions of JPY
Revenue
Cost of sales
FY2026
Revised
Forecasts Gross profit
FY2026
May 13
Forecasts
Change
Revenue
Cost of sales
Japan
88.5
50.7
37.8
U.S.
425.1
152.3
272.8
Other
51.4
43.0
8.4
Total
565.0
246.0
319.0
Gross profit
87.6
52.1
35.5
406.4
152.7
253.7
46.0
40.2
5.8
540.0
245.0
295.0
Revenue
Cost of sales
0.9
(1.4)
18.7
(0.4)
5.4
2.8
25.0
1.0
Gross profit
2.3
19.1
2.6
24.0
Japan
Higher gross profit driven by upward revisions to
TWYMEEG® sales forecast, with a limited
increase in cost of sales
U.S.
Higher gross profit mainly driven by pricingdriven revenue upside in 1H
Other
Higher gross profit reflecting stronger sales to
Europe
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
12
Research and Development
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
13
Research and Development
Development Pipeline (As of October 30, 2026)
Area
Psychiatry &
Neurology
Generic Name/Product Code
Revisions since the announcement in July 2026 are shown in red
Mechanism of Action, etc.
Planned Indication(s)
Development Stage
DSP-0038
Serotonin 5-HT2A receptor antagonist and serotonin 5-HT1A
receptor agonist
Alzheimer’s disease psychosis
Phase 1
DSP-0187
Selective orexin-2 receptor agonist
Narcolepsy
Phase 1
DSP-3456
Metabotropic glutamate receptor 2/3 negative allosteric
modulator (mGluR2/3 NAM)
Treatment-resistant depression
Phase 1
DSP-0378
Gamma-aminobutyric acid (GABA) A receptor positive
allosteric modulator
Progressive Myoclonic Epilepsy
Developmental Epileptic Encephalopathy
Phase 1
DSP-2342
Serotonin 5-HT2A and 5-HT7 receptor antagonist
To be determined
Phase 1
DSP-0551
Multi-ion channel modulator
Tremor associated with Parkinson’s disease
Phase 1
CT1-DAP001/DSP-1083 (Japan)
Allogeneic iPS [induced pluripotent stem] cell-derived
dopaminergic neural progenitor cells
Parkinson’s disease
CT1-DAP001/DSP-1083 (U.S.)
Allogeneic iPS cell-derived dopaminergic neural progenitor
cells
Parkinson’s disease/Investigator-initiated clinical
study, Company-sponsored clinical study
Phase 1/2
HLCR011(Japan)
Allogeneic iPS cell-derived retinal pigment epithelial cells
Retinal pigment epithelium tear
Phase 1/2
DSP-3077(U.S.)
Allogeneic iPS cell-derived retinal sheet
Retinitis pigmentosa
Phase 1/2
Enzomenib
Selective menin inhibitor
Acute leukemia
Phase 2
Nuvisertib
PIM1 kinase inhibitor
Myelofibrosis
Phase 1/2
SMP-3124
CHK1 inhibitor
Solid tumors
Phase 1/2
DSP-0390
EBP inhibitor
Glioblastoma
Phase 1
KSP-1007
β-lactamase inhibitor
Complicated urinary tract and intra-abdominal
infections, Hospital-acquired bacterial pneumonia
Phase 1
fH1/DSP-0546LP
Split, Adjuvanted vaccine
Influenza virus prophylaxis
Phase 1
Post-marketing clinical study
ongoing
Oncology
Others
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
14
Research and Development
Major Topics in Clinical Development (August 1 – October 30, 2026)
Psychiatry & Neurology
AMCHEPRY® / raguneprocel / CT1-DAP001 / DSP-1083
Parkinsonʼs disease
Japan:
・First patient transplantation completed in the post-marketing clinical study (Phase 4 study) of allogeneic iPS cell-derived
dopaminergic neural progenitor cells (See page 16 for details)
U.S. (CT1-DAP001/DSP-1083):
・Transplantations continued in the investigator-initiated study, and the first patient transplantation was completed in the companysponsored study (both Phase 1/2 studies of allogeneic iPS cell-derived dopaminergic neural progenitor cells)
DSP-3077 (U.S.)
Retinitis pigmentosa
・Retinal sheet transplantation was performed in multiple patients in the Phase 1/2 study (see page 17 for details)
Oncology
Enzomenib (U.S., Japan)
・Granted Breakthrough Therapy Designation in the U.S. for relapsed/refractory KMT2A-rearranged acute leukemia (October 21)
Others
fH1/DSP-0546LP
Universal influenza vaccine
・Final results from the Phase 1 study, including one-year follow-up, announced (see page 18 for details)
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
15
Research and Development
AMCHEPRY® Post-Marketing Clinical Study (Phase 4 Study) Schedule
Advancing site activation and patient enrollment readiness for the Phase 4 study
The first patient transplantation was completed at Kyoto University Hospital in October 2026
Approximately 1–2 patients are planned in FY2026, approximately 10 in FY2027, and approximately 10–20 in FY2028
Priority will be given to patients enrolled in the Phase 4 study. After study completion, treatment will expand to additional sites
and a broader patient population
FY2026
July
Transplantation
Schedule
Expected Timing
of Sites
Disclosure
August
September
October
November
December
1–2 patients (FY2026)
Product
IRB submission,
First patient
contract execution
manufacturing transplantation
and institutional review
completed
process
Kyoto University
Hospital
Osaka
Toneyama
Medical
Center
・Juntendo ・1 site in
University the Kansai
Hospital region
・Saitama ・1 site in
Medical the Tohoku
University region
Hospital
January
February
FY2027
FY2028
Approx. 10
patients
Approx. 10 –20
patients
March
・1 site in
the Chubu
region
Please note that inquiries regarding the AMCHEPRY® post-marketing clinical study (Phase 4 study) are not accepted by
participating medical institutions. Please contact us via our corporate inquiry form
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
16
Research and Development
Psychiatry & Neurology: Allogeneic iPS Cell-Derived Retinal Sheet (DSP-3077) for Retinitis Pigmentosa
Retinal sheet transplantation was performed in multiple patients in the U.S. Phase 1/2 study
The Q2 FY2026 milestone was achieved, and the clinical study is progressing as planned
About DSP-3077
A retinal sheet derived from allogeneic iPS cells containing abundant
photoreceptor precursor cells
Single subretinal transplantation into the eye with poorer visual acuity
Regenerative Medicine for
Retinitis Pigmentosa Using
DSP-3077
DSP-3077
Overview of U.S. Phase 1/2 Study (NCT06891885)
Photoreceptors / cell
nuclei / Synapses and
retinal neurons
Target disease
Retinitis pigmentosa
Study design
(target
enrollment)
Open-label, single-arm, dose-escalation
study; untreated fellow eye as control
(12 patients)
Primary endpoint Safety and tolerability
Secondary
Engraftment, efficacy, and others
endpoints
Retinal pigment
epithelial cells
(RPE cells)
Cohort
Patients
Photoreceptors
Cohort 1
4
patients
HM*
to approx. 0.05
Low dose
Cohort 2
4
patients
HM*
to approx. 0.05
High dose
Cohort 3
4
patients
Approx. 0.05 – 0.1
High dose
photoreceptor
Degeneration
Healthy Retina
DSP-3077
Transplantation
Retinitis Pigmentosa
DSP-3077
Transplantation for
Retinitis Pigmentosa
Visual acuity**
Dose***
- HM(hand motion) : visual acuity sufficient to distinguish the direction of hand movement.
** Visual acuity: best-corrected visual acuity assessed using the ETDRS chart. Study-eye eligibility
thresholds are hand motion, ETDRS 20 letters (approx. 0.05), and ETDRS 35 letters (approx. 0.1).
*** Low dose: 0.8–2.4 mm²; high dose: 2.4–6.4 mm²
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
17
Research and Development
Others: fH1/DSP-0546LP Universal Influenza Vaccine
Favorable safety and tolerability were observed through one year after administration,
and anti-LAH antibody titers remained elevated
A controlled human infection study is planned to begin by the end of FY2026
With fH1 antigen 2 μg
Time Course of Antibody Induction Against LAH*
Overview of the Phase 1 Study in Europe
144 healthy adults (ages 18–40)
Design
Randomized, placebo-controlled, double-blind
Administration Two intramuscular doses at three-week intervals
Safety and tolerability
Four weeks after
No serious adverse reactions
completion of dosing
Through
4週one year
after administration
No new major safety concerns;
generally favorable tolerability
1年
Exploratory Analyses Related to Protection Against Infection
持続
Increased anti-LAH IgG1 subclass
antibody titers
新規
Increased neutralizing activity
against the H1N1 strain
(n=12; n=11 for antigen 2 μg + adjuvant 5 μg)
Anti-LAH Antibody Titers (Unit/mL)
Subjects
DSP-0546LP Adjuvant
(Liposomal formulation)
1000
100
Antigen 2 μg alone
10
Placebo
+Adjuvant 10 μg
- Adjuvant 5 μg
- Adjuvant 2.5 μg
1
0
50
100
150
200
Day
250
300
350
Geometric mean ± 95% confidence interval
*LAH (Long Alpha Helix): A conserved antigenic region shared across a broad range of influenza viruses
Joint research under the AMED CiCLE program with the National Institutes of Biomedical Innovation, Health and Nutrition (NIBN).
See our September 30, 2026 press release for details.
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
18
Revisions since the announcement in July 2026 are shown in red
Research and Development
Key Development Products: Major Milestones Scheduled in FY2026 (as of October 30, 2026)
Area
Program
Q1
Q2
Q3
DSP-0378
Psychiatry
&
Neurology
Oncology
Initial PoC*
acquisition
(Progressive Myoclonic Epilepsy
Developmental Epileptic Encephalopathy)
CT1-DAP001 / DSP-1083
(Parkinson’s disease)
DSP-3077
(Japan) First transplantation 1
(Retinitis pigmentosa)
Phase 2
Completion of
enrollment for interim
analysis
Enzomenib
(Monotherapy,
relapsed or refractory NPM1-mutated
Acute Myeloid Leukemia)
Phase 2
Enrollment initiation
1 Post-marketing clinical study
2 Phase 1/2
(U.S.) First transplantation2
Enzomenib
(Monotherapy,
relapsed or refractory
KMT2A-rearranged Acute Leukemia)
Nuvisertib
(Combination with momelotinib,
newly diagnosed and relapsed or
refractory Myelofibrosis)
Remarks
Q4
NDA filing (Q1 FY2027)
Phase 2
Interim analysis
Top-line results
Phase 2
Completion of
enrollment for
interim analysis
3 To be determined in consultation
Phase 3
Decision on
recommended dose3
with the FDA
Phase 2
Decision on
recommended dose 3
SMP-3124
(Monotherapy, solid tumors)
4 One-year follow-up safety data,
Others
fH1/DSP-0546LP
(Universal Influenza Vaccine)
Final analysis of
1-year follow-up4
CHIS** study
Initiation
antibody persistence, and subtype
specific immune response
analyses (e.g., IgG2, IgG4)
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
- Initial PoC (Proof of Concept): Preliminary confirmation of efficacy in patients based on a limited number of cases ** Controlled Human Infection Studies: Human challenge studies
19
Appendix
<Contents>
P.21 Financial Results for Q2 FY2026
P.22 Financial Results for Q2 FY2026
P.23 Financial Results for Q2 FY2026
P.24 Financial Forecasts for FY2026
P.25 R&D
P.26 R&D
Financial Results for Q2 FY2026 (Full Basis)
Financial Position and Cash Flow
Prescription Trends of GEMTESA®
Revenue of Major Products in Japan
Product Launch Target
Regenerative Medicine/Cell Therapy
Launched Product and Development Pipeline
(RACTHERA Co., Ltd.)
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
20
Appendix (Financial Results for Q2 FY2026)
Financial Results for Q2 FY2026 (Full Basis)
Billions of JPY
Q2YTD
FY2025
Results
Revenue
Cost of sales
Gross profit
SG&A expenses
R&D expenses
Other operating income and expenses
Operating profit
Finance income and costs
Profit before taxes
Income tax expenses
Net profit attributable to owners of the parent
Q2YTD
FY2026
Results
Change
Value
%
227.1
89.7
137.4
266.5
123.5
143.0
39.4
33.8
5.5
17.3
37.7
4.0
76.6
17.5
52.8
78.7
23.8
1.8
2.2
6.2
(51.0)
2.8
35.6
96.2
(3.4)
42.3
(2.9)
(53.9)
0.5
(56.0)
92.8
(6.1)
98.9
39.4
1.1
38.2
(53.4)
7.2
(60.6)
(57.6)
(61.3)
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
21
Appendix (Financial Results for Q2 FY2026)
Financial Position and Cash Flow
Billions of JPY
B/S
Assets
Goodwill / Intangible assets
Trade and other receivables
Cash and deposit / Short-term loan receivable
Liabilities
Bonds and borrowings
Other non-current liabilities
Other current liabilities
Equity
Share capital
Capital surplus
(Ratio of equity attributable to owners of the parent
to total assets)
C/F
Operating CF
Investing CF
Financing CF
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of period
As of March
2026
804.6
371.6
131.4
44.3
512.1
217.2
23.5
50.8
292.5
22.4
0.0
36.4%
Q2 FY2025
18.0
27.6
(44.0)
23.1
38.5
As of Sep.
2026
851.1
361.7
152.0
77.8
419.9
139.7
15.2
32.6
431.1
71.3
48.3
50.7%
Q2 FY2026
16.7
0.5
17.6
44.3
77.8
Change
46.5
(9.9)
20.6
33.4
(92.2)
(77.5)
(8.3)
(18.2)
138.6
48.9
48.3
Repayment of borrowings
Increase due to issuance of new shares
Change
(1.4)
(27.1)
61.5
21.2
39.3
FY25: Proceeds from loss of control of subsidiaries
FY25: Repayment of borrowings
FY26: Proceeds from issuance of new shares, repayment
of borrowings
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
22
Appendix (Financial Results for Q2 FY2026)
Prescription Trends of GEMTESA®
GEMTESA® prescriptions, including total and new prescriptions, continued to increase despite the launch of Mirabegron
generics in Apr. 2024
K
K
TRx in β-3 Market
900
ジェムテサ
800
NBRx in β-3 Market
120
その他 β3受容体作動薬
ジェムテサ
その他 β3受容体作動薬
100
700
600
80
500
60
400
300
40
200
20
100
4 6 8 10 12 2 4 6 8 10 12 2 4 6 8 10 12 2 4 6 8 10 12 2 4 6 8
2022
2023
2024
FY
2025
2026
4 6 8 10 12 2 4 6 8 10 12 2 4 6 8 10 12 2 4 6 8 10 12 2 4 6 8
2022
2023
2024
2025
2026
FY
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
Source: Symphony Health, a HealthVerity Company, Metys®, April 2022 to September 2026
23
Appendix (Financial Forecasts for FY2026)
Revenue of Major Products in Japan
Billions of JPY
FY2026
May 13
Forecasts
FY2026
Revised
Forecasts
Change
Value
%
Japan
XEPLION®/XEPLION TRI®
®
LATUDA
TWYMEEG®
METGLUCO®
AG products
Others
Total
17.1
13.6
11.9
7.6
11.2
26.2
87.6
17.1
13.9
13.2
7.6
11.8
24.9
88.5
-
0.3
1.3
-
0.6
(1.3)
0.9
-
2.2
10.9
-
5.4
(5.0)
1.0
TWYMEEG® sales forecast revised
upward to reflect strong sales
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
24
Revisions since the announcement in July 2026 are shown in red
Appendix (Research and Development)
Product Launch Target (as of October 30, 2026)
FY2026
CT1-DAP001/DSP-1083
(Allogeneic iPS cell-derived
dopaminergic neural
progenitor cells)
(RACTHERA Co., Ltd.)
HLCR011
(Allogeneic iPS cellderived retinal pigment
epithelial cells)
(RACTHERA Co., Ltd.)
Enzomenib
(Selective menin inhibitor)
Nuvisertib
(PIM1 kinase inhibitor)
2027
2028
Psychiatry &
Neurology
2029
Parkinson’s disease
Oncology
2030
Development
in the U.S.
Post-marketing clinical study
ongoing
Retinal pigment
epithelium tear
Expand
indications
Expand
indications
Acute leukemia*
Myelofibrosis
Expand
indications
- Relapsed or refractory acute leukemia with KMT2A rearrangement or acute myeloid leukemia with NPM1 mutation
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
25
Revisions since the announcement in July 2026 are shown in red
Appendix (Research and Development)
Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (RACTHERA Co., Ltd.)
(as of October 30, 2026)
Brand name/Cell type
Product code
Indications
JP/
US
RETHYMIC®
Congenital athymia
US
Dopaminergic neural
progenitor cells
(Allo iPS cell-derived)
CT1-DAP001/DSP-1083
Retinal pigment
epithelial cells
(Allo iPS cell-derived)
HLCR011
Retinal sheet
(3D retinal tissue)
(Allo iPS cell-derived)
Parkinson’s
disease
(Allo iPS cell-derived)
Nephron progenitor
cells (organ)
(Auto/ Allo iPS cell-based
induced)
Clinical
research
Phase 1/2
Phase 3
Approval
application
Approval→
Launch
16
JP
Conditional and time-limited
4
US
5
approval obtained in Japan
(Mar. 2026)
Retinal pigment
epithelium tear
5
JP
JP
2
Retinitis pigmentosa
5
US
DSP-3077
Neural progenitor cells
Pre-clinical
JP
3 7
Spinal cord injury
US
Kidney failure
JP/
US
- Kyoto University Hospital 2. Kobe City Eye Hospital 3. Keio University Hospital 4. University of California San Diego 5. Company-sponsored clinical study
- Post-marketing clinical study (Phase 4 study) ongoing in Japan 7. For subacute spinal cord injury
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
26